RETROSPECTIVE CLAIMS DATABASE ANALYSIS TO EXPLORE DIFFERENCES IN HEART FAILURE PATIENTS WITH AND WITHOUT IRON DEFICIENCY OR ANEMIA

Author(s)

Jacob C1, Altevers J1, Haas J1, Hardt T2, Erath F2, Braun S1
1Xcenda GmbH, Hannover, Germany, 2Vifor Pharma Deutschland GmbH, München, Germany

OBJECTIVES: This descriptive study explores the demographics, NYHA (NY Heart Association) functional class, healthcare utilization and costs in Germany for Heart Failure (HF) patients with and without iron deficiency and/or anemia (ID/A). METHODS: We conducted a claims database analysis with an age and sex adjusted sample from the Health Risk Institute research database containing anonymized healthcare claims of over 4 million statutory health insured persons. HF patients were identified by ICD-10-GM codes (I50.-) in the inpatient and outpatient setting in 2013. They were stratified into HF patients without ID/A and HF patients with ID/A using ICD-10-GM codes (D50.-, D50.0, D50.8, D50.9, E61.1) or ATC codes for prescribed iron medication (B03A). HF patients with ID/A were further stratified into three subgroups: No treatment for ID/A, oral iron treatment and intravenous iron treatment. Health outcomes and costs were assessed in a 1-year time frame. RESULTS: In total, 172,394 (4,538 per 100,000) HF patients were identified for 2013 in the database. Of these, 11.1% were diagnosed with ID/A. The mean age was 79.1 years for HF patients with ID/A and 76.7 years for HF patients without ID/A. 58.5% with ID/A and 54.1% without ID/A were female. The majority of HF patients with ID/A did not receive iron treatment (56.1%). Oral iron was administered in 37.9% and intravenous iron in 6.0%. HF patients with ID/A presented more often with NYHA classes III and IV and had higher all-cause mortality (17.8% vs. 10.8%). Healthcare utilization regarding hospitalizations and outpatient visits was also higher for these patients. Furthermore, HF patients with ID/A caused higher overall healthcare costs than HF patients without ID/A. CONCLUSIONS: Real world evidence suggests that HF patients with ID/A are on average older and sicker with a higher proportion of women than in HF patients without ID/A. They present with higher all-cause mortality, healthcare utilization and costs.

Conference/Value in Health Info

2016-10, ISPOR Europe 2016, Vienna, Austria

Value in Health, Vol. 19, No. 7 (November 2016)

Code

PCV138

Topic

Economic Evaluation, Health Service Delivery & Process of Care

Topic Subcategory

Cost/Cost of Illness/Resource Use Studies, Prescribing Behavior

Disease

Cardiovascular Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×